双功能CXCR4靶向脂质体在白血病中的应用:功能阻断与药物递送
本文描述了一种新设计的CXCR4靶向拮抗分子BAT1的生物学评价,并展示将其整合入脂质体药物递送系统后,可向慢性淋巴细胞白血病(CLL)细胞高水平递送癌症治疗药物。BAT1可阻断CXCR4/CXCL12相互作用,BAT1脂质体特异性摄取并递送货物至细胞核,诱导更多CLL细胞死亡。
要点
- BAT1靶向并拮抗CXCR4,减少ERK磷酸化和细胞迁移至无CXCL12刺激水平(P < .001)。
- BAT1脂质体在孵育3小时内被特异性摄取并将治疗货物递送至细胞核。
- BAT1脂质体在24小时后诱导的CLL细胞死亡显著多于对照脂质体(P = .004)。
核心结论
- BAT1脂质体药物递送系统可同时阻断CXCL12诱导的迁移和细胞内信号传导并递送治疗货物,可能成为多种血液病的治疗手段。
研究设计与样本
- 本文描述了一种新CXCR4靶向拮抗分子BAT1的设计及生物学评价,并评估其整合入脂质体后的靶向、拮抗和药物递送功能。
主要发现
- BAT1减少ERK磷酸化和细胞迁移至无CXCL12刺激时水平(P < .001)。
- BAT1脂质体在孵育3小时内被特异性摄取并将治疗货物递送至细胞核。
- BAT1脂质体在24小时后诱导的CLL细胞死亡显著多于对照脂质体(P = .004)。
临床怎么用
- BAT1脂质体药物递送系统具有模块化、通用性和临床相关性,治疗货物可根据所治疗疾病定制。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CXC chemokine receptor 4 (CXCR4) is overexpressed by a broad range of hematological disorders, and its interaction with CXC chemokine ligand 12 (CXCL12) is of central importance in the retention and chemoprotection of neoplastic cells in the bone marrow and lymphoid organs. In this article, we describe the biological evaluation of a new CXCR4-targeting and -antagonizing molecule (BAT1) that we designed and show that, when incorporated into a liposomal drug delivery system, it can be used to deliver cancer therapeutics at high levels to chronic lymphocytic leukemia (CLL) cells. CXCR4 targeting and antagonism by BAT1 were demonstrated alone and following its incorporation into liposomes (BAT1-liposomes). Antagonism of BAT1 against the CXCR4/CXCL12 interaction was demonstrated through signaling inhibition and function blocking: BAT1 reduced ERK phosphorylation and cell migration to levels equivalent to those seen in the absence of CXCL12 stimulation (P < .001). Specific uptake of BAT1-liposomes and delivery of a therapeutic cargo to the cell nucleus was seen within 3 hours of incubation and induced significantly more CLL cell death after 24 hours than control liposomes (P = .004). The BAT1 drug-delivery system is modular, versatile, and highly clinically relevant, incorporating elements of proven clinical efficacy. The combined capabilities to block CXCL12-induced migration and intracellular signaling while simultaneously delivering therapeutic cargo mean that the BAT1-liposome drug-delivery system could be a timely and relevant treatment of a range of hematological disorders, particularly because the therapeutic cargo can be tailored to the disease being treated.
引用
- McCallion C, Peters AD, Booth A, et al. Dual-action CXCR4-targeting liposomes in leukemia: function blocking and drug delivery. Blood Adv. 2019. PMID: 31292126. doi:10.1182/bloodadvances.2019000098
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。